Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

398 ARTÍCULOS , VIENDO DEL 121 AL 135

Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients

Wang L, Ying J, Fan P, Weamer EA, DeMichele-Sweet MAA, Lopez OL, Kofler JK, Sweet RA.

Am J Geriatr Psychiatry. 2019 Sep;27(9):908-917. doi: 10.1016/j.jagp.2019.03.016. Epub 2019 Mar 27.

[Drug treatment of Alzheimer's dementia : Status quo and perspectives]

Müller P, Fendt M, Müller NG.

Internist (Berl). 2019 Jul;60(7):761-768. doi: 10.1007/s00108-019-0625-4.

Alzheimer's disease: future drug development and the blood-brain barrier

Pardridge WM.

Expert Opin Investig Drugs. 2019 Jul;28(7):569-572. doi: 10.1080/13543784.2019.1627325. Epub 2019 Jun 4.

Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Hampel H, Lista S, Mango D, Nisticò R, Perry G, Avila J, Hernandez F, Geerts H, Vergallo A; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2019;69(3):615-629. doi: 10.3233/JAD-190197.

Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga S, Fujishiro H, Takechi H.

J Alzheimers Dis. 2019;69(4):1031-1039. doi: 10.3233/JAD-190256.

An augmented reality approach for ADL support in Alzheimer's disease: a crossover trial

Rohrbach N, Gulde P, Armstrong AR, Hartig L, Abdelrazeq A, Schröder S, Neuse J, Grimmer T, Diehl-Schmid J, Hermsdörfer J.

J Neuroeng Rehabil. 2019 Jun 3;16(1):66. doi: 10.1186/s12984-019-0530-z.

Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches

González JF, Alcántara AR, Doadrio AL, Sánchez-Montero JM.

Expert Opin Drug Discov. 2019 Sep;14(9):879-891. doi: 10.1080/17460441.2019.1623201. Epub 2019 Jun 5.

Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease

Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctôt KL.

Am J Geriatr Psychiatry. 2019 Nov;27(11):1161-1173. doi: 10.1016/j.jagp.2019.05.002. Epub 2019 May 8.

Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment

Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, Abbaszadeh H, Aghebati-Maleki L, Pourlak T, Mehdizadeh A, Yousefi M.

Life Sci. 2019 Aug 15;231:116564. doi: 10.1016/j.lfs.2019.116564. Epub 2019 Jun 13.

Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?

Willbold D, Kutzsche J.

Molecules. 2019 Jun 15;24(12):2237. doi: 10.3390/molecules24122237.

Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology

Hossain MF, Uddin MS, Uddin GMS, Sumsuzzman DM, Islam MS, Barreto GE, Mathew B, Ashraf GM.

Mol Neurobiol. 2019 Dec;56(12):8255-8276. doi: 10.1007/s12035-019-01660-3. Epub 2019 Jun 17.

Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML.

Curr Top Med Chem. 2019;19(19):1694-1711. doi: 10.2174/1568026619666190619115735.

The overlap between epilepsy and Alzheimer's disease and the consequences for treatment

Powell G, Ziso B, Larner AJ.

Expert Rev Neurother. 2019 Jul;19(7):653-661. doi: 10.1080/14737175.2019.1629289. Epub 2019 Jun 26.

Cholinesterase inhibitors as Alzheimer's therapeutics (Review)

Sharma K.

Mol Med Rep. 2019 Aug;20(2):1479-1487. doi: 10.3892/mmr.2019.10374. Epub 2019 Jun 11.

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis

Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H.

Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias